Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes

QTc dispersion (QTcd) tended to be decreased at 24 weeks and was significantly decreased at 2 years after dapagliflozin treatment. In the subgroup with QTcd?53.7 ms (median), QTcd was significantly decreased at 24 weeks and remained improved for 2 years. Dapagliflozin also significantly reduced Tpea...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Tatsuya, Miki, Takayuki, Furukawa, Shinya, Matsuura, Bunzo, Hiasa, Yoichi, Ohnishi, Hirofumi, Tanno, Masaya, Miura, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825944/
https://www.ncbi.nlm.nih.gov/pubmed/31090258
http://dx.doi.org/10.1111/jdi.13063
_version_ 1783464982560636928
author Sato, Tatsuya
Miki, Takayuki
Furukawa, Shinya
Matsuura, Bunzo
Hiasa, Yoichi
Ohnishi, Hirofumi
Tanno, Masaya
Miura, Tetsuji
author_facet Sato, Tatsuya
Miki, Takayuki
Furukawa, Shinya
Matsuura, Bunzo
Hiasa, Yoichi
Ohnishi, Hirofumi
Tanno, Masaya
Miura, Tetsuji
author_sort Sato, Tatsuya
collection PubMed
description QTc dispersion (QTcd) tended to be decreased at 24 weeks and was significantly decreased at 2 years after dapagliflozin treatment. In the subgroup with QTcd?53.7 ms (median), QTcd was significantly decreased at 24 weeks and remained improved for 2 years. Dapagliflozin also significantly reduced Tpeak‐Tend/QT in a subgroup with Tpeak‐Tend/QT?0.25 (median).[Image: see text]
format Online
Article
Text
id pubmed-6825944
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68259442019-11-07 Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes Sato, Tatsuya Miki, Takayuki Furukawa, Shinya Matsuura, Bunzo Hiasa, Yoichi Ohnishi, Hirofumi Tanno, Masaya Miura, Tetsuji J Diabetes Investig Letters to the Editor QTc dispersion (QTcd) tended to be decreased at 24 weeks and was significantly decreased at 2 years after dapagliflozin treatment. In the subgroup with QTcd?53.7 ms (median), QTcd was significantly decreased at 24 weeks and remained improved for 2 years. Dapagliflozin also significantly reduced Tpeak‐Tend/QT in a subgroup with Tpeak‐Tend/QT?0.25 (median).[Image: see text] John Wiley and Sons Inc. 2019-05-15 2019-11 /pmc/articles/PMC6825944/ /pubmed/31090258 http://dx.doi.org/10.1111/jdi.13063 Text en © 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letters to the Editor
Sato, Tatsuya
Miki, Takayuki
Furukawa, Shinya
Matsuura, Bunzo
Hiasa, Yoichi
Ohnishi, Hirofumi
Tanno, Masaya
Miura, Tetsuji
Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
title Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
title_full Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
title_fullStr Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
title_full_unstemmed Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
title_short Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
title_sort longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825944/
https://www.ncbi.nlm.nih.gov/pubmed/31090258
http://dx.doi.org/10.1111/jdi.13063
work_keys_str_mv AT satotatsuya longitudinalimpactofdapagliflozintreatmentonventricularrepolarizationheterogeneityinpatientswithtype2diabetes
AT mikitakayuki longitudinalimpactofdapagliflozintreatmentonventricularrepolarizationheterogeneityinpatientswithtype2diabetes
AT furukawashinya longitudinalimpactofdapagliflozintreatmentonventricularrepolarizationheterogeneityinpatientswithtype2diabetes
AT matsuurabunzo longitudinalimpactofdapagliflozintreatmentonventricularrepolarizationheterogeneityinpatientswithtype2diabetes
AT hiasayoichi longitudinalimpactofdapagliflozintreatmentonventricularrepolarizationheterogeneityinpatientswithtype2diabetes
AT ohnishihirofumi longitudinalimpactofdapagliflozintreatmentonventricularrepolarizationheterogeneityinpatientswithtype2diabetes
AT tannomasaya longitudinalimpactofdapagliflozintreatmentonventricularrepolarizationheterogeneityinpatientswithtype2diabetes
AT miuratetsuji longitudinalimpactofdapagliflozintreatmentonventricularrepolarizationheterogeneityinpatientswithtype2diabetes

Ejemplares similares